Guardant Health, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GH research report →
Companyguardanthealth.com
Guardant Health, Inc. , a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- CEO
- Helmy Eltoukhy
- IPO
- 2018
- Employees
- 1,999
- HQ
- Palo Alto, CA, US
Price Chart
Valuation
- Market Cap
- $14.68B
- P/E
- -33.55
- P/S
- 13.59
- P/B
- -80.26
- EV/EBITDA
- -39.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 64.90%
- Op Margin
- -41.43%
- Net Margin
- -40.10%
- ROE
- 184.27%
- ROIC
- -27.50%
Growth & Income
- Revenue
- $982.02M · 32.88%
- Net Income
- $-416,277,000 · 4.61%
- EPS
- $-3.32 · 6.74%
- Op Income
- $-436,298,000
- FCF YoY
- 15.23%
Performance & Tape
- 52W High
- $120.74
- 52W Low
- $36.36
- 50D MA
- $89.38
- 200D MA
- $86.61
- Beta
- 1.49
- Avg Volume
- 1.97M
Get TickerSpark's AI analysis on GH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Tariq Musa | other | 250 |
| May 18, 26 | Tariq Musa | sell | 116 |
| May 15, 26 | Tariq Musa | other | 250 |
| May 17, 26 | Hidalgo Medina Manuel | other | 232 |
| May 17, 26 | Hidalgo Medina Manuel | other | 232 |
| May 15, 26 | Chudova Darya | other | 8,705 |
| May 15, 26 | Chudova Darya | other | 4,679 |
| May 15, 26 | Chudova Darya | other | 8,705 |
| May 12, 26 | Talasaz AmirAli | sell | 50,000 |
| Apr 30, 26 | Krognes Steve E. | other | 154 |
Our GH Coverage
We haven't published any research on GH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GH Report →